Solventum Corp

Solventum Corp(SOLV)の株式分析

$91.120

+0.191 (+0.21%)終値時点

Loading chart…
High
91.700
Open
90.980
VWAP
91.17
Vol
678.87K
Mkt Cap
Low
90.690
Amount
61.89M
EV/EBITDA, TTM
15.21

Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.

AI analysis of Solventum Corp (SOLV)

buy

Solventum Corp is a strong buy at the current price of $91.12, supported by a recent earnings report that showed a 9.5% year-over-year organic growth and an EPS of $2.55, which exceeded estimates by 33.51%. The company's forward P/E ratio of 13.39 suggests it is undervalued compared to its growth potential. However, the main risk is its high debt-to-equity ratio of 110.12%, which could impact financial stability if not managed carefully.

バリュエーション指標

The current forward P/E ratio for Solventum Corp (SOLV) is 13.39, compared to its 5-year average forward P/E of 12.31.

Forward P/E

Fair
5Y Average P/E
12.31
Current P/E
13.39
割高
13.54
割安
11.08

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
10.32
Current EV/EBITDA
15.21
割高
13.78
割安
6.86

Forward P/S

Strongly Overvalued
5Y Average P/S
1.49
Current P/S
1.82
割高
1.65
割安
1.33

Alphio AI Price Scenarios for SOLV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SOLV

$79.34

シナリオ価格

B

Base

Base · 50%SOLV

$74.78

シナリオ価格

B

Bear

Bear · 25%SOLV

$71.27

シナリオ価格

Whales holding SOLV

3

3M Company

+ HoldingSOLV

+20.15%

3M Return

E

Equity Investment Corporation

+ HoldingSOLV

+10.66%

3M Return

R

Ruffer LLP

+ HoldingSOLV

+9.30%

3M Return

T

Trian Fund Management, L.P.

+ HoldingSOLV

+6.47%

3M Return

D

Diamond Hill Capital Management, Inc.

+ HoldingSOLV

+5.48%

3M Return

H

Hikari Power Ltd.

+ HoldingSOLV

+3.84%

3M Return

SOLV FAQ — answered by Alphio AI

Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation. It operates in the Healthcare sector.

Solventum Corp is a strong buy at the current price of $91.12, supported by a recent earnings report that showed a 9.5% year-over-year organic growth and an EPS of $2.55, which exceeded estimates by 33.51%. The company's forward P/E ratio of 13.39 suggests it is undervalued compared to its growth potential. However, the main risk is its high debt-to-equity ratio of 110.12%, which could impact financial stability if not managed carefully.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める